SLDB Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of 12.65%. Solid Biosciences, Inc.'s return on equity of -77.74% beat Electromed, Inc.'s return on equity of 18.89%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 158.15%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that Solid Biosciences, Inc. has higher upside potential than Electromed, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Electromed, Inc..

Solid Biosciences, Inc. has a beta of 2.975, which suggesting that the stock is 197.54% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Solid Biosciences, Inc.'s net income of -$45.8M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of -36.3%. Solid Biosciences, Inc.'s return on equity of -77.74% beat Myomo, Inc.'s return on equity of -68.35%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 158.15%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than Solid Biosciences, Inc., analysts believe Myomo, Inc. is more attractive than Solid Biosciences, Inc..

Solid Biosciences, Inc. has a beta of 2.975, which suggesting that the stock is 197.54% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Solid Biosciences, Inc.'s net income of -$45.8M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of -862.39%. Solid Biosciences, Inc.'s return on equity of -77.74% beat VolitionRX Ltd.'s return on equity of --.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 158.15%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than Solid Biosciences, Inc., analysts believe VolitionRX Ltd. is more attractive than Solid Biosciences, Inc..

Solid Biosciences, Inc. has a beta of 2.975, which suggesting that the stock is 197.54% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Solid Biosciences, Inc.'s net income of -$45.8M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of 3.93%. Solid Biosciences, Inc.'s return on equity of -77.74% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 158.15%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Solid Biosciences, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Xtant Medical Holdings, Inc..

Solid Biosciences, Inc. has a beta of 2.975, which suggesting that the stock is 197.54% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Solid Biosciences, Inc.'s net income of -$45.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.